Third-Generation Sequencing Technology Market Report 2026

Third-Generation Sequencing Technology Market Overview

• Third-Generation Sequencing Technology market size has reached to $14 billion in 2025 • Expected to grow to $26.71 billion in 2030 at a compound annual growth rate (CAGR) of 13.7% • Growth Driver: Increasing Adoption Of Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomics And Tailored Treatments • Market Trend: Development Of Ultra-Rapid And Scalable Sequencing Systems • North America was the largest region in 2025.

What Is Covered Under Third-Generation Sequencing Technology Market?

Third-generation sequencing technology refers to advanced DNA or RNA sequencing methods that read single molecules in real-time, often producing long continuous reads without the need for polymerase chain reaction (PCR) amplification. Its primary purpose is to provide highly accurate, comprehensive genomic and transcriptomic information, enabling the detection of structural variants, epigenetic modifications, and complex regions that are challenging for earlier sequencing methods. The main technology types of third-generation sequencing technology are single-molecule real-time sequencing (SMRT), transcription-mediated amplification (TMA), nanopore sequencing, sequencing by synthesis (SBS), and others. Single-molecule real-time sequencing (SMRT is an advanced technique that tracks DNA synthesis by enzymes in real time, detecting fluorescent signals of each base without the need for template amplification. The different workflow involves sample preparation, sequencing, data analysis, and data storage or management, and is widely used in applications such as genomics, transcriptomics, epigenomics, metagenomics, personalized medicine, and synthetic biology, serving end users such as academic institutions, clinical laboratories, pharmaceutical and biotechnology companies, research organizations, and government and non-profit institutions.

What Is The Third-Generation Sequencing Technology Market Growth Forecast?

The third-generation sequencing technology market size is expected to see rapid growth in the next few years. It will grow to $26.71 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to precision medicine expansion, clinical diagnostics adoption, reduction in sequencing costs, integration with ai analytics, population genomics initiatives. Major trends in the forecast period include long-read sequencing technologies, real-time dna sequencing, clinical genomics adoption, single-molecule sequencing, portable sequencing platforms.

Global Third-Generation Sequencing Technology Market Segmentation

1) By Technology Type: Single-Molecule Real-Time Sequencing (SMRT), Nanopore Sequencing 2) By Workflow: Sample Preparation, Sequencing, Data Analysis, Data Interpretation, Data Storage And Management 3) By Application: Genomics, Transcriptomics, Epigenomics, Metagenomics, Personalized Medicine, Synthetic Biology 4) By End-User: Academic Institutions, Clinical Laboratories, Pharmaceutical And Biotechnology Companies, Research Organizations, Government And Non-Profit Organizations Subsegments: 1) By Single-Molecule Real-Time Sequencing (SMRT): Zero-Mode Waveguides (ZMWs), Circular Consensus Sequencing (CCS), High-Fidelity (HiFi) Reads 2) By Nanopore Sequencing: Portable Nanopore Sequencers, Benchtop Nanopore Sequencers, High-Throughput Nanopore Platforms

What Is The Driver Of The Third-Generation Sequencing Technology Market?

The increasing adoption of personalized medicine is expected to propel the growth of the third-generation sequencing technology market going forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The increasing adoption of personalized medicine is primarily due to advancements in genomics, which enable precise identification of genetic variations and tailored treatments for individuals. Third-generation sequencing technology enhances personalized medicine by delivering long-read, high-accuracy genomic data, enabling precise identification of genetic variations. It supports tailored treatment strategies by providing comprehensive insights into individual genomes, improving clinical outcomes and advancing precision healthcare. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the increasing adoption of personalized medicine is driving the growth of the third-generation sequencing technology industry.

Key Players In The Global Third-Generation Sequencing Technology Market

Major companies operating in the third-generation sequencing technology market are Oxford Nanopore Technologies, Pacific Biosciences, Quantapore, Ultima Genomics, BGI Genomics, MGI Tech, Complete Genomics, Stratos Genomics, VisiGen Biotechnologies, Helicos Biosciences, Genia Technologies, Electronic Bio Sciences, Quantum Biosystems, Base4 Innovation, Nabsys, Chronix Biomedical, Roche, Nanopore Diagnostics, GenapSys, SomaLogic

Global Third-Generation Sequencing Technology Market Trends and Insights

Major companies operating in the third-generation sequencing technology market are focusing on developing advanced sequencing platforms, such as ultra-rapid and scalable sequencing systems, to boost research efficiency, enhance clinical applicability, and reduce turnaround times and costs. Ultra-rapid and scalable sequencing systems refer to innovative technologies that enable high-throughput, real-time genomic analysis with exceptional speed and accuracy, facilitating comprehensive genomic profiling across diverse applications. For instance, in February 2025, Roche Holding AG, a Switzerland-based pharmaceutical company, launched Sequencing by Expansion (SBX) technology. It is a fully integrated, next-generation sequencing system featuring a patented biochemical process that encodes DNA or RNA sequences into measurable surrogate polymers called Xpandomers, enabling highly accurate single-molecule nanopore sequencing. The SBX platform includes ultra-rapid, scalable sequencing capabilities and automated data analysis, delivering whole-genome sequencing results in hours rather than days without extensive manual intervention.

What Are Latest Mergers And Acquisitions In The Third-Generation Sequencing Technology Market?

In August 2023, PacBio, a US-based provider of high-quality and highly accurate sequencing solutions, acquired Apton Biosystems for up to $110 million. With this acquisition, PacBio aims to accelerate the development of a high-throughput short-read sequencing platform by integrating its Sequencing by Binding (SBB) chemistry with Apton’s advanced optics and image processing technology. Apton Biosystems is a US-based company developing a high-throughput short-read sequencer designed to enable the sequencing of billions of DNA clusters on a single flow cell.

Regional Outlook

North America was the largest region in the third-generation sequencing technology market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Third-Generation Sequencing Technology Market?

The third-generation sequencing technology market consists of revenues earned by entities by providing services such as whole genome sequencing, transcriptome sequencing, epigenetic analysis, de novo genome assembly, single-cell sequencing, and structural variant detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The third-generation sequencing technology market also includes sales of sequencing instruments, reagents, flow cells, sample preparation kits, nanopore devices, optical mapping systems, microfluidic chips, and sample preparation instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.